Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
This transaction represented 100% of CFO Ryan Savitz's direct equity holdings, resulting in a post-sale direct ownership of zero shares. The activity was executed entirely in direct holdings through the exercise and sale of employee stock options, with no indirect (trust, LLC, or family entity) participation. These 10 stocks could mint the next wave of millionaires › On Dec. 4, 2025, Ryan Savitz, CFO & CBO of Dianthus Therapeutics (NASDAQ:DNTH) , exercised 20,000 stock options and immediately sold the resulting shares for a total consideration of $903,600, according to an SEC Form 4 filing Metric Value Shares sold (direct) Transaction value ~$903,600 Post-transaction shares (direct) Post-transaction value (direct ownership) ~$0 Transaction value based on SEC Form 4 weighted average purchase price ($45.18); post-transaction value was $0 as no direct shares remained post-sale. How did the transaction affect Savitz Ryan's direct ownership position? The sale o
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Assessing Dianthus Therapeutics (DNTH) Valuation As Price To Book Sits Near 3x And Shares Show Mixed Returns [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Truist Financial Corporation from $56.00 to $63.00. They now have a "buy" rating on the stock.MarketBeat
- Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]Yahoo! Finance
DNTH
Earnings
- 11/5/25 - Miss
DNTH
Sec Filings
- 1/12/26 - Form 8-K
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- DNTH's page on the SEC website